https://scholars.lib.ntu.edu.tw/handle/123456789/580200
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Kim S.J. | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Song Y.-Q. | en_US |
dc.contributor.author | Tay K. | en_US |
dc.contributor.author | Hong X.-N. | en_US |
dc.contributor.author | Cao J. | en_US |
dc.contributor.author | Kim J.S. | en_US |
dc.contributor.author | Eom H.S. | en_US |
dc.contributor.author | Lee J.H. | en_US |
dc.contributor.author | Zhu J. | en_US |
dc.contributor.author | Chang K.-M. | en_US |
dc.contributor.author | Reksodiputro A.H. | en_US |
dc.contributor.author | Tan D. | en_US |
dc.contributor.author | Goh Y.T. | en_US |
dc.contributor.author | Lee J. | en_US |
dc.contributor.author | Intragumtornchai T. | en_US |
dc.contributor.author | Chng W.-J. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Lim S.T. | en_US |
dc.contributor.author | Suh C. | en_US |
dc.contributor.author | Kwong Y.-L. | en_US |
dc.contributor.author | Kim W.S. | en_US |
dc.date.accessioned | 2021-09-01T01:53:44Z | - |
dc.date.available | 2021-09-01T01:53:44Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885184821&doi=10.1016%2fj.ejca.2013.07.006&partnerID=40&md5=ca94d70ef74f03f1dda8239c48de286c | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/580200 | - |
dc.description.abstract | Background Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. Methods Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis. Results HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p < 0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p < 0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases. Conclusions This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. ? 2013 Elsevier Ltd. All rights reserved. | - |
dc.relation.ispartof | European Journal of Cancer | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adefovir; clevudine; corticosteroid; cyclophosphamide; doxorubicin; entecavir; hepatitis B core antibody; hepatitis B surface antigen; lamivudine; prednisone; rituximab; telbivudine; tenofovir; vincristine; virus DNA; adult; antiviral therapy; article; B cell lymphoma; chemotherapy; cross-sectional study; drug efficacy; female; hepatitis B; Hepatitis B virus; human; large cell lymphoma; major clinical study; male; priority journal; prophylaxis; retrospective study; risk factor; treatment duration; virus reactivation; B-cell; Hepatitis B virus; Lymphoma; Rituximab; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Asia; Biological Markers; Cross-Sectional Studies; DNA, Viral; Endemic Diseases; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Prospective Studies; Retrospective Studies; Treatment Outcome; Viral Load; Virus Activation | - |
dc.title | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.ejca.2013.07.006 | - |
dc.identifier.pmid | 23910494 | - |
dc.identifier.scopus | 2-s2.0-84885184821 | - |
dc.relation.pages | 3486-3496 | - |
dc.relation.journalvolume | 49 | - |
dc.relation.journalissue | 16 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。